In 2023…… On May 12th, LaNova announced that AstraZeneca will receive an exclusive global license for LM-305’s research, development, and commercialization. LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) targeting GPRC5D. LaNova Medicines will receive an immediate payment of $55 million and $545 million in additional development and commercial milestone payments. On May 19th, the clinical trial application for OriCAR-017 […]
At the end of the first quarter of 2023, many pharmaceutical companies disclosed major adjustments to their R&D pipelines in their quarterly reports. Eli Lilly also announced they will give up on three clinical trials which include TRPA1 antagonist. Eli Lilly’s TRPA1 antagonist was acquired from Hydra Biosciences in 2018 and is mainly used for […]